2026年潜在关键新药上市预测与管线分析（英）

1As a supplement to our well-known quarterly Outlook report, Biomedtracker is pleased to present a longer-term look at some key late-stage drugs projected to hit the market in 2026. These drugs represent new drug classes, major changes to standards of care, and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Healthcare. This report will enable you to:•Identify high-impact launches – Discover drugs that could achieve blockbuster potential, transform treatment landscapes, or launch in new therapeutic classes.•Anticipate competitive shifts – Understand which therapies may change the standard of care and disrupt existing markets.•Track key regulatory milestones – Follow critical catalysts, including PDUFA dates, pivotal trial readouts, and first approvals.•Support strategic decisions – Leverage our expert insights to enhance portfolio planning, competitors monitoring, and drive informed planning.•Access concise analyst insights – Benefit from clear, one-page summaries for each highlighted drug with therapy area, company details, likelihood of approval, and links to deeper analysis on BMT.Key Potential Drug Launches in 2026More details about each drug can be viewed on Biomedtracker by clicking the  icon.CONTENTS PAGEBIOMEDTRACKER.COMKEY POTENTIAL DRUG LAUNCHES IN 2026 (AS OF JULY 2025)A close up of a logoAI-generated content may be incorrect.2MethodologyScope and ObjectiveThis report highlights pharmaceutical candidates that were in Phase III or later stages of development as of July 2025, with select Phase IIb/II/III drugs included based on the presence of near-term regulatory catalysts. The primary objective is to identify drugs with significant potential for market impact (blockbuster potential), clinical relevance, and regulatory advancement.Strategic RelevanceThe report focuses on drugs that demonstrate:• Large Market Potential (Blockbuster)• Major Change to Standard of Care• Representation of Novel Drug ClassesThese criteria ensure that the report captures candidates with the highest likelihood of influencing both clinical practice and commercial landscapes.Selection CriteriaDrugs were selected based on the following catalysts:• Product Launch Catalysts• Approval Decision Catalysts• Regulatory Filing Catalysts (e.g., NDA/BLA submissions)• Phase III or Pivotal Trial ReadoutsBlockbuster PotentialA blockbuster drug is defined as one generating $1 billion or more in annual revenue. While it remains uncertain whether any of the drugs listed will reach this benchmark, the report aims to spotlight those with potential to do so.CONTENTS PAGEBIOMEDTRACKER.COMKEY POTENTIAL DRUG LAUNCHES IN 2026 (AS OF JULY 2025)A close up of a logoAI-generated content may be incorrect.3AIA&IAllergyAllergyDermatologyDermatologyEndocrineEndocrineHematologyHematologyInfectious DiseasesInfectious DiseasesNeurologyNeurologyOncologyOncologyCVCVMetabolicMetabolicRespiratoryRespiratoryPsychiatryPsychiatryThis report c